Predicta Biosciences, which develops diagnostic and therapeutic tools for precision oncology, raised a $23.4 million Series A, new CEO Brian McKernan tells Axios Pro exclusively.
Why it matters: Predicta could begin raising its Series B in the next 12 to 18 months, he says.
